Ondas Holdings: Strong Story, Weak Math—Wait for Proof Points

What happened

Ondas reported Q2 2026 revenue of $83.8 million, a thirteen-fold increase year-over-year, driven primarily by acquisitions and defense demand, with pro forma backlog reaching $757 million. However, adjusted EBITDA losses widened to $50.6 million from $10.9 million in Q1, gross margin fell to 43% from 53%, and G&A expenses ballooned to $128 million including $60.3 million in stock compensation. The company's share count has climbed rapidly to 569.8 million shares outstanding, with an additional 45 million DZYNE contingent shares due in January 2027 and large warrant and option overhangs, raising concerns about per-share value dilution. Despite $1.39 billion in liquidity providing near-term solvency, the market is becoming less tolerant of widening losses without clear conversion of backlog into profitable revenue. A Seeking Alpha article echoed these concerns, stating it likes the story but not the math yet, reinforcing the view that investors should wait for Q3 and Q4 evidence of revenue conversion and margin improvement before committing capital.

Implication

Investors should monitor Q3 2026 revenue against the guided $140M-$155M range and sequential improvement in adjusted EBITDA losses, as failure to hit those marks would undermine the H2 conversion thesis. The upcoming January 2027 issuance of 45 million DZYNE shares is a clear catalyst for further dilution, and management's capital allocation decisions will be scrutinized for their impact on per-share value. Near-term solvency is not in question given the $1.39 billion liquidity position, but the market is likely to continue punishing the stock if losses remain wide relative to revenue growth. A successful Q4 with operating-platform adjusted EBITDA profitability and evidence of organic growth would shift sentiment positively, potentially justifying an upgrade to a BUY. Until those proof points emerge, the risk-reward skews unfavorable at current prices, and the attractive entry level remains near $7.25.

Thesis delta

The core thesis remains unchanged: Ondas is a promising defense-drone consolidator with real demand but unproven per-share economics, warranting a WAIT rating. The new article introduces no new information but sharpens the focus on the dilution math, specifically the 45 million DZYNE contingent shares due in January 2027. This reinforces the existing concern that share-funded growth may erode value even if operational targets are met, keeping the attractive entry point at $7.25.